Diabetes mellitus and the neutrophil to lymphocyte ratio predict overall survival in non-viral hepatocellular carcinoma treated with transarterial chemoembolization

Oncology Letters

Volumn 7, Issue 5, 2014, Pages 1704-1710

  Zhang, Jiangguo ^a   Gong, Fengyun ^b   Li, Ling ^a   Zhao, Manzhi ^a   Song, Jianxin ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Dept of Hand Surgery   (China)

Author keywords

Chemoembolization; Diabetes mellitus; Hepatocellular carcinoma; Neutrophil to lymphocyte ratio; Non viral; Overall survival

Indexed keywords

CISPLATIN; FLUOROURACIL; GAMMA GLUTAMYLTRANSFERASE; MITOMYCIN;

ADULT; ARTICLE; CANCER PROGNOSIS; CHEMOEMBOLIZATION; DIABETES MELLITUS; FEMALE; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEUTROPHIL; ORAL GLUCOSE TOLERANCE TEST; OVERALL SURVIVAL; PORTAL VEIN THROMBOSIS; PROSPECTIVE STUDY; SURVIVAL RATE; TUMOR VOLUME;

EID: 84896264891     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.1896     Document Type: Article

References (38)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
2. Shi J, Zhu L, Liu S and Xie WF: A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China. Brit J Cancer 92: 607-612, 2005.
3. Chang MH, You SL, Chen CJ, et al; Taiwan Hepatoma Study Group: Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 101: 1348-1355, 2009.
4. Papatheodoridis GV, Lampertico P, Manolakopoulos S and Lok A: Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 53: 348-356, 2010.
5. Shiratori Y, Ito Y, Yokosuka O, et al; Tokyo-Chiba Hepatitis Research Group: Antiviral therapy for cirρtic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 142: 105-114, 2005.
6. Hatanaka K, Kudo M, Fukunaga T, et al: Clinical characteristics of NonBNonC- HCC: Comparison with HBV and HCV related HCC. Intervirology 50: 24-31, 2007.
7. Llovet JM and Bruix J: Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 48 (Suppl 1): S20-S37, 2008.
8. Lencioni R, Chen XP, Dagher L and Venook AP: Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved? Oncologist 15 (Suppl 4): S42-S52, 2010.
9. Llovet JM and Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 37: 429-442, 2003.
10. Nagaoki Y, Hyogo H, Aikata H, et al: Recent trend of clinical features in patients with hepatocellular carcinoma. Hepatol Res 42: 368-375, 2012.
11. Koh WP, Wang R, Jin A, Yu MC and Yuan JM: Diabetes mellitus and risk of hepatocellular carcinoma: findings from the Singapore Chinese Health Study. Brit J Cancer 108: 1182-1188, 2013.
12. Djiogue S, Nwabo Kamdje AH, Vecchio L, et al: Insulin resistance and cancer: the role of insulin and IGFs. Endocr Relat Cancer 20: R1-R17, 2013.
13. Mehta NN, McGillicuddy FC, Anderson PD, et al: Experimental endotoxemia induces adipose inflammation and insulin resistance in humans. Diabetes 59: 172-181, 2010.
14. Grivennikov SI, Greten FR and Karin M: Immunity, inflammation, and cancer. Cell 140: 883-899, 2010.
15. Alison MR, Nicholson LJ and Lin WR: Chronic inflammation and hepatocellular carcinoma. Recent Results Cancer Res 185: 135-148, 2011.
16. Ting CT, Chen RC, Chen CC, Liu MH, Chu D and Kuo NW: Diabetes worsens the surgical outcomes in cirρtic patients with hepatocellular carcinoma. Tohoku J Exp Med 227: 73-81, 2012.
17. Huo TI, Hsu CY, Huang YH, et al: Diabetes mellitus as an independent prognostic predictor and its association with renal dysfunction in patients with hepatocellular carcinoma. Liver Int 30: 198-207, 2010.
18. Huo TI, Wu JC, Lui WY, et al: Differential mechanism and prognostic impact of diabetes mellitus on patients with hepatocellular carcinoma undergoing surgical and nonsurgical treatment. Am J Gastroenterol 99: 1479-1487, 2004.
19. Limaye AR, Clark V, Soldevila-Pico C, et al: Neutrophil-lymphocyte ratio predicts overall and recurrence-free survival after liver transplantation for hepatocellular carcinoma. Hepatol Res 43:757-764, 2012.
20. Bruix J and Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma. Hepatology 42: 1208-1236, 2005.
21. Lagiou P, Kuper H, Stuver SO, Tzonou A, Trichopoulos D and Adami HO: Role of diabetes mellitus in the etiology of hepatocellular carcinoma. J Natl Cancer Inst 92: 1096-1099, 2000.
22. Shau WY, Shao YY, Yeh YC, et al: Diabetes mellitus is associated with increased mortality in patients receiving curative therapy for hepatocellular carcinoma. Oncologist 17: 856-862, 2012.
23. Kaibori M, Ishizaki M, Matsui K, Kitade H, Matsui Y and Kwon AH: Evaluation of metabolic factors on the prognosis of patients undergoing resection of hepatocellular carcinoma. J Gastroenterol Hepatol 26: 536-543, 2011.
24. Kawamura Y, Ikeda K, Arase Y, et al: Diabetes mellitus worsens the recurrence rate after potentially curative therapy in patients with hepatocellular carcinoma associated with nonviral hepatitis. J Gastroenterol Hepatol 23: 1739-1746, 2008.
25. Connolly GC, Safadjou S, Kashyap R, Chen R, Orloff MS and Hezel AF: Diabetes mellitus impacts risk of macrovascular invasion in patients undergoing transplantation for hepatocellular carcinoma. BMC Gastroenterol 13: 9, 2013.
26. Giannelli G, Pierri F, Trerotoli P, et al: Occurrence of portal vein tumor thrombus in hepatocellular carcinoma affects prognosis and survival.: A retrospective clinical study of 150 cases. Hepatol Res 24: 50, 2002.
27. Zhao WC, Fan LF, Yang N, Zhang HB, Chen BD and Yang GS: Preoperative predictors of microvascular invasion in multinodular hepatocellular carcinoma. Eur J Surg Oncol 39: 858-864, 2013.
28. McNally ME, Martinez A, Khabiri H, et al: Inflammatory markers are associated with outcome in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization. Ann Surg Oncol 20: 923-928, 2013.
29. Tavares-Murta BM, Mendonça MA, Duarte NL, et al: Systemic leukocyte alterations are associated with invasive uterine cervical cancer. Int J Gynecol Cancer 20: 1154-1159, 2010.
30. Imai Y, Kubota Y, Yamamoto S, et al: Neutrophils enhance invasion activity of human cholangiocellular carcinoma and hepatocellular carcinoma cells: an in vitro study. J Gastroenterol Hepatol 20: 287-293, 2005.
31. McDonald B, Spicer J, Giannais B, Fallavollita L, Brodt P and Ferri LE: Systemic inflammation increases cancer cell adhesion to hepatic sinusoids by neutrophil mediated mechanisms. Int J Cancer 125: 1298-1305, 2009.
32. Wu Y, Zhao Q, Peng C, Sun L, Li XF and Kuang DM: Neutrophils promote motility of cancer cells via a hyaluronan-mediated TLR4/PI3K activation loop. J Pathol 225: 438-447, 2011.
33. Siddique A and Kowdley KV: Insulin resistance and other metabolic risk factors in the pathogenesis of hepatocellular carcinoma. Clin Liver Dis 15: 281-296, 2011.
34. Oh JS, Kucab JE, Bushel PR, et al: Insulin-like growth factor-1 inscribes a gene expression profile for angiogenic factors and cancer progression in breast epithelial cells. Neoplasia 4: 204-217, 2002.
35. Piecewicz SM, Pandey A, Roy B, Xiang SH, Zetter BR and Sengupta S: Insulin-like growth factors promote vasculogenesis in embryonic stem cells. PloS One 7: e32191, 2012.
36. Brandau S, Dumitru CA and Lang S: Protumor and antitumor functions of neutrophil granulocytes. Semin Immunopathol 35: 163-176, 2013.
37. Zhang JB, Chen Y, Zhang B, et al: Prognostic significance of serum gamma-glutamyl transferase in patients with intermediate hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Eur J Gastroenterol Hepatol 23: 787-793, 2011.
38. Oh BS, Jang JW, Kwon JH, et al: Prognostic value of C-reactive protein and neutrophil-to-lymphocyte ratio in patients with hepatocellular carcinoma. BMC cancer 13: 78, 2013.